• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

作为与人类B细胞肿瘤融合伙伴的小鼠×人类异源杂交瘤

Mouse x human heterohybridomas as fusion partners with human B cell tumors.

作者信息

Carroll W L, Thielemans K, Dilley J, Levy R

出版信息

J Immunol Methods. 1986 May 1;89(1):61-72. doi: 10.1016/0022-1759(86)90032-3.

DOI:10.1016/0022-1759(86)90032-3
PMID:3084658
Abstract

Surface idiotype (Id) of B cell malignancies is an excellent tumor-specific marker. We have, however, recently described heterogeneity of tumor Id in some cases. We therefore sought a way to isolate, reliably and efficiently, different species of idiotype from a potentially heterogeneous population. In this report we demonstrate our success using a series of mouse X human heterohybridomas as fusion partners with human B cell tumors. Three lines (K6H6/B5, K6H9/G12, SBC/H20) demonstrated excellent fusion efficiency with 75%-85% of wells plated containing hybrids. Two cell lines, K6H9/G12 and SBC/H20 had a tendency to secrete a single Ig chain (heavy or light chain), whereas the K6H6/B5 cell line secreted whole immunoglobulin (Ig) in greater than 80% of the hybrids. This line secreted significant amounts of Ig (2.73 micrograms/ml/10(6) cells) and was relatively stable in culture. Since this line has such a high fusion efficiency the products of normal B cells admixed with tumor may be recovered, allowing the opportunity of isolating host anti-tumor antibodies. In order to prove that hybrids were derived from the tumor, Southern blot analysis of rearranged DNA was performed in selected cases. Fusions with this line provide the potential for recovering many different species of idiotype in a mixed population. This will facilitate the production of mouse monoclonal anti-idiotype antibodies against many variants and against different idiotopes.

摘要

B细胞恶性肿瘤的表面独特型(Id)是一种出色的肿瘤特异性标志物。然而,我们最近在某些病例中描述了肿瘤Id的异质性。因此,我们寻求一种方法,能够从潜在的异质群体中可靠且高效地分离出不同种类的独特型。在本报告中,我们展示了使用一系列小鼠X人异源杂交瘤作为与人B细胞肿瘤融合伙伴的成功经验。三个细胞系(K6H6/B5、K6H9/G12、SBC/H20)表现出优异的融合效率,接种的孔中有75%-85%含有杂交细胞。两个细胞系K6H9/G12和SBC/H20倾向于分泌单一的Ig链(重链或轻链),而K6H6/B5细胞系在超过80%的杂交细胞中分泌完整的免疫球蛋白(Ig)。该细胞系分泌大量的Ig(2.73微克/毫升/10⁶个细胞),并且在培养中相对稳定。由于该细胞系具有如此高的融合效率,与肿瘤混合的正常B细胞产物可能被回收,从而有机会分离宿主抗肿瘤抗体。为了证明杂交细胞源自肿瘤,在选定的病例中进行了重排DNA的Southern印迹分析。与该细胞系的融合为在混合群体中回收许多不同种类的独特型提供了可能性。这将有助于生产针对许多变体和不同独特位的小鼠单克隆抗独特型抗体。

相似文献

1
Mouse x human heterohybridomas as fusion partners with human B cell tumors.作为与人类B细胞肿瘤融合伙伴的小鼠×人类异源杂交瘤
J Immunol Methods. 1986 May 1;89(1):61-72. doi: 10.1016/0022-1759(86)90032-3.
2
Strategies for production of monoclonal anti-idiotype antibodies against human B cell lymphomas.针对人类B细胞淋巴瘤产生单克隆抗独特型抗体的策略。
J Immunol. 1984 Jul;133(1):495-501.
3
Influence of avidity and idiotope recognition on the modulation of surface immunoglobulin on malignant human B cells by rat monoclonal anti-idiotype antibodies.亲和力和独特型表位识别对大鼠单克隆抗独特型抗体调节人恶性B细胞表面免疫球蛋白的影响。
J Immunol. 1986 Apr 15;136(8):2983-8.
4
Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38C13: characterization and use as probes for the biology of the tumor in vivo and in vitro.抗小鼠B细胞淋巴瘤38C13的单克隆抗独特型抗体:特性及作为体内外肿瘤生物学探针的应用
Hybridoma. 1985 Fall;4(3):191-209. doi: 10.1089/hyb.1985.4.191.
5
Idiotype variant cell populations in patients with B cell lymphoma.B细胞淋巴瘤患者的独特型变异细胞群体。
J Exp Med. 1986 Nov 1;164(5):1566-80. doi: 10.1084/jem.164.5.1566.
6
Immunoselection of B cell hybridomas with anti-idiotypic antisera to study the role of heavy and light chains for idiotype expression and antibody activity.用抗独特型抗血清对B细胞杂交瘤进行免疫选择,以研究重链和轻链在独特型表达及抗体活性中的作用。
J Immunol. 1984 May;132(5):2485-90.
7
UC 729-6, a human lymphoblastoid B-cell line useful for generating antibody-secreting human-human hybridomas.UC 729-6,一种可用于产生分泌抗体的人-人杂交瘤的人淋巴母细胞样B细胞系。
Proc Natl Acad Sci U S A. 1983 Oct;80(20):6327-31. doi: 10.1073/pnas.80.20.6327.
8
Generation of heavy chain-loss mutants in a B cell hybrid mediated by syngeneic idiotype-specific spleen cells.在同基因独特型特异性脾细胞介导的B细胞杂交瘤中产生重链缺失突变体。
J Immunol. 1984 Sep;133(3):1677-82.
9
Anti-idiotypic antibodies recognizing stable epitopes limit the emergence of idiotype variants in a murine B cell lymphoma.识别稳定表位的抗独特型抗体限制了小鼠B细胞淋巴瘤中独特型变体的出现。
J Immunol. 1990 Mar 15;144(6):2436-45.
10
Idiotype variants emerging after anti-idiotype monoclonal antibody therapy of a murine B cell lymphoma.鼠源B细胞淋巴瘤经抗独特型单克隆抗体治疗后出现的独特型变体。
J Immunol. 1989 Jan 1;142(1):343-51.

引用本文的文献

1
Substantially Improved Electrofusion Efficiency of Hybridoma Cells: Based on the Combination of Nanosecond and Microsecond Pulses.杂交瘤细胞电融合效率的显著提高:基于纳秒和微秒脉冲的组合。
Bioengineering (Basel). 2022 Sep 7;9(9):450. doi: 10.3390/bioengineering9090450.
2
Capture and display of antibodies secreted by hybridoma cells enables fluorescent on-cell screening.杂交瘤细胞分泌抗体的捕获和显示可实现荧光细胞筛选。
MAbs. 2019 Apr;11(3):546-558. doi: 10.1080/19420862.2019.1574520. Epub 2019 Feb 22.
3
Hybridoma-Derived Idiotype Vaccine for Lymphoma: Approval Must Wait.
用于淋巴瘤的杂交瘤衍生独特型疫苗:批准尚需时日。
Pharmaceuticals (Basel). 2010 Mar 15;3(3):667-678. doi: 10.3390/ph3030667.
4
Use of Human Hybridoma Technology To Isolate Human Monoclonal Antibodies.利用人杂交瘤技术分离人单克隆抗体。
Microbiol Spectr. 2015 Feb;3(1):AID-0027-2014. doi: 10.1128/microbiolspec.AID-0027-2014.
5
Pneumococcal IgA1 protease subverts specific protection by human IgA1.肺炎链球菌 IgA1 蛋白酶颠覆了人 IgA1 的特异性保护作用。
Mucosal Immunol. 2014 Mar;7(2):249-56. doi: 10.1038/mi.2013.41. Epub 2013 Jul 3.
6
Nonstereotyped lymphoma B cell receptors recognize vimentin as a shared autoantigen.非定型淋巴瘤 B 细胞受体将波形蛋白识别为共同自身抗原。
J Immunol. 2013 May 1;190(9):4887-98. doi: 10.4049/jimmunol.1300179. Epub 2013 Mar 27.
7
Idiotype vaccines for lymphoma: Potential factors predicting the induction of immune responses.淋巴瘤的独特型疫苗:预测免疫反应诱导的潜在因素。
World J Clin Oncol. 2011 Jun 10;2(6):237-44. doi: 10.5306/wjco.v2.i6.237.
8
Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.在缓解期 1 时使用患者特异性肿瘤源性抗原进行接种可改善滤泡性淋巴瘤的无病生存。
J Clin Oncol. 2011 Jul 10;29(20):2787-94. doi: 10.1200/JCO.2010.33.3005. Epub 2011 May 31.
9
Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures.淋巴瘤的独特型疫苗:原理验证及临床试验失败情况
Nat Rev Cancer. 2009 Sep;9(9):675-81. doi: 10.1038/nrc2717.
10
Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma.接种疫苗后抗独特型抗体反应与滤泡性淋巴瘤更好的总生存期相关。
Blood. 2009 Jun 4;113(23):5743-6. doi: 10.1182/blood-2009-01-201988. Epub 2009 Apr 3.